Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Merck
Cantor Fitzgerald
Daiichi Sankyo
Moodys
McKesson
Federal Trade Commission
Accenture
AstraZeneca
Express Scripts

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,155,716

« Back to Dashboard

Which drugs does patent 9,155,716 protect, and when does it expire?

Patent 9,155,716 protects LUMIGAN and is included in one NDA.

This patent has thirty-two patent family members in twenty-one countries.
Summary for Patent: 9,155,716
Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/826,047
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,155,716

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y A METHOD OF LOWERING INTRAOCULAR PRESSURE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,155,716

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,851,504 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,309,605 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,933,120 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,338,479 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,586,630 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,933,127 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,772,338 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,524,777 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,278,353 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,299,118 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,155,716

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101177598 ➤ Sign Up
South Korea 20070113292 ➤ Sign Up
Japan 5899267 ➤ Sign Up
Japan 2008511539 ➤ Sign Up
Japan 5367946 ➤ Sign Up
Japan 5563515 ➤ Sign Up
Japan 2014144983 ➤ Sign Up
Hong Kong 1104211 ➤ Sign Up
Israel 185744 ➤ Sign Up
Spain 2324058 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
US Department of Justice
Moodys
Cantor Fitzgerald
Daiichi Sankyo
QuintilesIMS
Teva
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot